-transparent.png){kind=logo}
In a randomized double-blind study the gastroduodenal tolerability of daily 500 mg acetylsalicylic acid (ASA, CAS 50-78-2) in combination with 250 mg glycine (CAS 56-40-6) (Godamed) and 500 mg ASA without addition of glycine were evaluated in 20 healthy volunteers giving upper GI-endoscopy. Both ASA-preparations have been taken over a period of 4 weeks. Endoscopic controls were performed at entry, and repeated after 7, 14 and 28 days of treatment. Both ASA-preparations induced comparable gastroduodenal damages during the whole test period: The lesions score of both groups on day 7, 14 and day 28 was almost identical. In contrast to plain ASA, where 9 of 10 volunteers reported gastrointestinal side effects, all subjects receiving ASA in combination with glycine did not complain from any dyspeptic symptoms, i.e. epigastric pain etc. The reasons for the apparent better tolerability of ASA in combination with glycine are discussed.
P Müller, and
H G Dammann, and
H Bergdolt, and
B Simon
June 1995,
Arzneimittel-Forschung,
P Müller, and
H G Dammann, and
H Bergdolt, and
B Simon
June 1997,
Arzneimittel-Forschung,
P Müller, and
H G Dammann, and
H Bergdolt, and
B Simon
May 1991,
Digestive diseases and sciences,
P Müller, and
H G Dammann, and
H Bergdolt, and
B Simon
January 1983,
Arzneimittel-Forschung,
P Müller, and
H G Dammann, and
H Bergdolt, and
B Simon
September 2003,
Alimentary pharmacology & therapeutics,
P Müller, and
H G Dammann, and
H Bergdolt, and
B Simon
September 2004,
International journal of clinical pharmacology and therapeutics,
P Müller, and
H G Dammann, and
H Bergdolt, and
B Simon
January 1984,
Gastroenterologie clinique et biologique,
P Müller, and
H G Dammann, and
H Bergdolt, and
B Simon
December 1991,
The Journal of sports medicine and physical fitness,
P Müller, and
H G Dammann, and
H Bergdolt, and
B Simon
January 2007,
The American journal of Chinese medicine,
P Müller, and
H G Dammann, and
H Bergdolt, and
B Simon
January 2022,
Frontiers in pharmacology,
